Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended De ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results